Clinical Diagnosis and Treatment of Monoclonal Gammopathy of Renal Significance

doi:10.12114/j.issn.1007-9572.2021.00.410

Abstract

Abstract: Monoclonal gammopathy of renal significance（MGRS） is a kind of renal damage mediated by monoclonal immunoglobulin（Ig） secreted by low-grade lymphoplasmacytic proliferative diseases.It is an early stage of the disease and is not enough to diagnose multiple myeloma（MM） or lymphoma.This paper analyzed the clinical characteristics，diagnosis and treatment process with a differential diagnosis of renal damage of 1 case of MM with renal damage and 3 cases of different types of MGRS admitted to Department of Hematology，West Hospital of Beijing Chao-yang Hospital from March 2018 to February 2020.Following that，a systematic review was conducted based on the case report and related literature，and recommendations were obtained，such as bortezomib-based option is recommended for patients with abnormal plasma cell clone and rituximab-based option is recommended for those with abnormal proliferation of B lymphocyte clone.It is suggested that for a patient with monoclonal Ig or unexplained renal disease，early renal biopsy is needed to confirm whether he has MGRS.If MGRS is confirmed，then its classification should be determined following the diagnosis consensus and process proposed by the International Kidney and Monoclonal Gammopathy Research Group，which will contribute to early delivery of clone-directed targeted therapy，thereby improving the renal function and prognosis of the patient.

Key words: Monoclonal, Immunoglobulin, Plasma cells, Proliferation, Multiple myeloma, Diagnosis, Therapy

摘要： 肾意义的单克隆免疫球蛋白血症（MGRS）是由低级别淋巴浆细胞增殖性疾病分泌的单克隆免疫球蛋白（Ig）介导的肾损害，为疾病早期阶段，尚不足以诊断为多发性骨髓瘤（MM）或淋巴瘤。本文分析了2018年3月—2020年2月首都医科大学附属北京朝阳医院西院血液科收治的1例MM合并肾损害和3例不同类型的MGRS患者的临床特点及诊治过程，对其肾损害进行了鉴别诊断，并结合病例和文献进行了系统分析。建议对表达浆细胞克隆或B淋巴细胞克隆的患者分别采用硼替佐米或利妥昔单抗为基础的治疗方案，提示临床医生对存在单克隆Ig和无法解释的肾脏疾病患者，需早期进行肾活检以确诊MGRS，遵循国际肾病和单克隆免疫球蛋白病研究组（IKMG）提出的诊断共识和诊断流程，进一步明确MGRS的诊断分型，有利于早期进行克隆指导的靶向治疗，改善患者的肾功能和预后。

关键词: 单克隆, 免疫球蛋白, 浆细胞, 增殖, 多发性骨髓瘤, 诊断, 治疗

WEI Yujun,LI Xin,SHEN Man, et al. Clinical Diagnosis and Treatment of Monoclonal Gammopathy of Renal Significance　[J]. Chinese General Practice, 2021, 24(18): 2359-2363. DOI: 10.12114/j.issn.1007-9572.2021.00.410.
魏宇君,李新,申曼等. 肾意义的单克隆免疫球蛋白血症病例报道并文献复习[J]. 中国全科医学, 2021, 24(18): 2359-2363. DOI: 10.12114/j.issn.1007-9572.2021.00.410.

References

［1］LEUNG N，BRIDOUX F，BATUMAN V，et al．The evaluation of monoclonal gammopathy of renal significance：a consensus report of the International Kidney and Monoclonal Gammopathy Research Group［J］．Nat Rev Nephrol，2019，15（1）：45-59．DOI：10.1038/s41581-018-0077-4.
［2］MOSEBACH J，THIERJUNG H，SCHLEMMER H.P，et al．Multiple myeloma guidelines and their recent updates：implications for imaging［J］．Rofo，2019，191（11）：998-1009．DOI：10.1055/a-0897-3966.
［3］LIM W H，LIM E M，MCDONALD S.Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine［J］．Nephrology：Carlton，2006，11（3）：250-256．DOI：10.1111/j.1440-1797.2006.00560.x.
［4］RAJKUMAR S.V.Multiple myeloma：2020 update on diagnosis risk-stratification and management［J］．Am J Hematol，2020，95（5）：548-567．DOI：10.1002/ajh.25791.
［5］DANZIGER S A，MCCONNELL M，GOCKLEY J，et al．Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma：a cohort study of patients in the total therapy clinical trials［J］．PLoS Med，2020，17（11）：e1003323．DOI：10.1371/journal.pmed.1003323.
［6］KYLE R A，LARSON D R，THERNEAU T M，et al．Long-term follow-up of monoclonal gammopathy of undetermined significance［J］．N Engl J Med，2018，378（3）：241-249．DOI：10.1056/NEJMoa1709974.
［7］GO R S，RAJKUMAR S V.How I manage monoclonal gammopathy of undetermined significance［J］．Blood，2018，131（2）：163-173．DOI：10.1182/blood-2017-09-807560.
［8］KUMAR S K，CALLANDER N S，HILLENGASS J，et al．NCCN guidelines insights：multiple myeloma，version 1.2020［J］．J Natl Compr Canc Netw，2019，17（10）：1154-1165．DOI：10.6004/jnccn.2019.0049.
［9］BATKO K，MALYSZKO J，JURCZYSZYN A，et al．The clinical implication of monoclonal gammopathies：monoclonal gammopathy of undetermined significance and of renal significance［J］．Nephrol Dial Transplant，2019，34（9）：1440-1452．DOI：10.1093/ndt/gfy259.
［10］LEUNG N，BRIDOUX F，HUTCHISON C A，et al．Monoclonal gammopathy of renal significance：when MGUS is no longer undetermined or insignificant［J］．Blood，2012，120（22）：4292-4295．DOI：10.1182/blood-2012-07-445304.
［11］FERMAND J P，BRIDOUX F，KYLE R A，et al．How I treat monoclonal gammopathy of renal significance （MGRS）［J］．Blood，2013，122（22）：3583-3590．DOI：10.1182/blood-2013-05-495929.
［12］KOBAYASHI H，TERAO T，TSUSHIMA T，et al．Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma［J］．Cancer Med，2020，9（12）：4460-4466．DOI：10.1002/cam4.3050.
［13］JAIN A，HAYNES R，KOTHARI J，et al．Pathophysiology and management of monoclonal gammopathy of renal significance［J］．Blood Adv，2019，3（15）：2409-2423．DOI：10.1182/bloodadvances.2019031914.
［14］OORTGIESEN B E，AZAD R，HEMMELDER M H，et al．The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment：a nationwide Dutch population-based study［J］．Haematologica，2018，103（7）：e311-314．DOI：10.3324/haematol.2017.184754.
［15］杨光忠，王晶，付丽娜，等.含或不含硼替佐米的联合化疗治疗伴肾功能不全的初诊多发性骨髓瘤患者的疗效分析［J］．中华血液学杂志，2010，31（6）：423-425．DOI：10.3760/cma.j.issn.0253-2727.2010.06.017.
YANG G Z，WANG J，FU L N，et al．Analysis of the therapeutic effect of chemotherapy with or without bortezomib on primary multiple myeloma patients with renal insufficiency［J］．Chinese Journal of Hematology，2010，31（6）：423-425.DOI：10.3760/cma.j.issn.0253-2727.2010.06.017.
［16］安娜，李新，申曼，等.以肾功能不全起病的多发性骨髓瘤69例临床分析［J］．中华内科杂志，2016，55（10）：764-768．DOI：10.3760/cma.j.issn.0578-1426.2016.10.008.
AN N，LI X，SHEN M，et al．A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency［J］．Chinese Journal of Internal Medicine，2016，55（10）：764-768．DOI：10.3760/cma.j.issn.0578-1426.2016.10.008.
［17］BASSET M，NUVOLONE M，PALLADINI G，et al．Novel challenges in the management of immunoglobulin light chain amyloidosis：from the bench to the bedside［J］．Expert Rev Hematol，2020，13（9）：1003-1015．DOI：10.1080/17474086.2020.1803060.
［18］WEISS B M，WONG S W，COMENZO R L.Beyond the plasma cell：emerging therapies for immunoglobulin light chain amyloidosis［J］．Blood，2016，127（19）：2275-2280．DOI：10.1182/blood-2015-11-681650.
［19］DISPENZIERI A，ARENDT B，DASARI S，et al．Blood mass spectrometry Detects Residual Disease Better than Standard Techniques in Immunoglobulin light chain amyloidosis［J］．Clin Lymphoma Myeloma Leuk，2019，19（10）：e313．DOI：10.1016/j.clml.2019.09.514.
［20］KHERA A，PANITSAS F，DJEBBARI F，et al．Long term outcomes in monoclonal gammopathy of renal significance［J］．Br J Haematol，2019，186（5）：706-716．DOI：10.1111/bjh.15987.
［21］BRIDOUX F，LEUNG N，HUTCHISON C A，et al．Diagnosis of monoclonal gammopathy of renal significance［J］．Kidney Int，2015，87（4）：698-711．DOI：10.1038/ki.2014.408.
［22］LARSEN C P，BELL J M，HARRIS A A，et al．The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation［J］．Mod Pathol，2011，24（11）：1462-1469．DOI：10.1038/modpathol.2011.104.
［23］STOKES M B，VALERI A M，HERLITZ L，et al．Light chain proximal tubulopathy：clinical and pathologic characteristics in the modern treatment era［J］．J Am Soc Nephrol，2016，27（5）：1555-1565．DOI：10.1681/asn.2015020185.
［24］STEINER N，G?BEL G，SUCHECKI P，et al．Monoclonal gammopathy of renal significance （MGRS） increases the risk for progression to multiple myeloma：an observational study of 2935 MGUS patients［J］．Oncotarget，2018，9（2）：2344-2356．DOI：10.18632/oncotarget.23412.
［25］CIOCCHINI M，MUSSO C G.Why renal biopsy is crucial in monoclonal gammopathy of renal significance （MGRS）［J］．Int Urol Nephrol，2019，51（5）：899-900．DOI：10.1007/s11255-019-02131-3.
［26］AMAADOR K，PEETERS H，MINNEMA M C，et al．Monoclonal gammopathy of renal significance （MGRS） histopathologic classification，diagnostic workup，and therapeutic options［J］．Neth J Med，2019，77（7）：243-254.
［27］KLOMJIT N，LEUNG N，FERVENZA F，et al．Rate and predictors of finding monoclonal gammopathy of renal significance （MGRS） lesions on kidney biopsy in patients with monoclonal gammopathy［J］．J Am Soc Nephrol，2020，31（10）：2400-2411．DOI：10.1681/asn.2020010054.

[1]	ZHENG Boyue, FU Jiyi, WU Jiafei, WANG Jun, LI Hui. Study on the Efficacy and Safety of Carfilzomib in the Treatment of Multiple Myeloma [J]. Chinese General Practice, 2025, 28(30): 3806-3814.
[2]	LI Hao, LI Peijin, LIU Tingting, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, Working Group on Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Cancer Pain. Guidelines on the Diagnosis and Treatment of Cancer Pain by Integrated Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2025, 28(30): 3729-3740.
[3]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[4]	PAN Qi, REN Jingjing, MA Fanghui, HU Mengjie. Survey of General Practitioners' Cognition and Needs for AI Assisted Diagnosis and Treatment Systems [J]. Chinese General Practice, 2025, 28(25): 3127-3136.
[5]	CHEN Fei, WANG Jinying, YU Haibo, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, ZHANG Tianyu, HUANG Zhongxia. Significance of Elevated Urinary NGAL, TIM-1, VCAM-1 and Activin A in Patients with New Diagnosed Multiple Myeloma [J]. Chinese General Practice, 2025, 28(22): 2740-2749.
[6]	Chinese Geriatrics Society, General Practice Branch of Zhejiang Medical Association, the Expert Collaboration Group on Medically Unspecified Disease in General Practice. Expert Consensus on the Diagnosis, Treatment, and Management of Emaciation (2025) [J]. Chinese General Practice, 2025, 28(21): 2577-2594.
[7]	BIAN Ying, YIN Gang, ZHANG Zixun, TAO Hongbing. The Mechanism of Information Construction Enabling High-quality Development of Compact County-level Medical Consortium [J]. Chinese General Practice, 2025, 28(19): 2426-2432.
[8]	LIU Hongya, YU Dehua. Construction and Practice of Clinical Diagnosis and Treatment Technology Combining General Practice and Specialist in Shanghai Community [J]. Chinese General Practice, 2025, 28(19): 2390-2397.
[9]	DENG Yaqian, CAO Chunli, MA Jinmei, LI Wenxiao, XU Zelin, CHENG Jing, LI Jun. Predictive Value of S-Detect Combined with Virtual Touch Tissue Imaging Quantification in Axillary Lymph Node Metastasis of Breast Cancer [J]. Chinese General Practice, 2025, 28(17): 2149-2155.
[10]	LI Jie, DU Yue, SHAO Shen, PAN Dong, ZHANG Yaxin. The Operational Efficiency of Traditional Chinese Medicine Diagnosis and Treatment Services in Primary Medical Institutions in Tianjin Based on DEA and SFA [J]. Chinese General Practice, 2025, 28(16): 1980-1986.
[11]	GU Jie, HUANG Yanyan. Diagnosis and Comprehensive Management of Rare Diseases: the Indispensable Role of General Practitioners [J]. Chinese General Practice, 2025, 28(16): 1955-1960.
[12]	Chinese Academy Society of Sleep Medicine, Chinese Medical Doctor Association, Sleep Medicine Group, China Neurologist Association. Chinese Guideline for Diagnosis and Treatment of Co-morbid Insomnia and Obstructive Sleep Apnea (2024) [J]. Chinese General Practice, 2025, 28(11): 1289-1303.
[13]	HUANG Lujie, ZHANG Xiaoying, YU Shasha. Risk Factors, Prognosis and Rapid Screening in Patients with Acute Aortic Dissection Complicated with Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(09): 1100-1105.
[14]	MA Xiaoxuan, WANG Rongqi. Research Progress in Metabolomics for HCC Diagnosis and Treatment [J]. Chinese General Practice, 2025, 28(08): 1017-1022.
[15]	SONG Fenfen, LI Shengmian. Real-World Study of Camrelizumab-based Regimen for Locally Advanced and Metastatic Esophageal Cancer [J]. Chinese General Practice, 2025, 28(07): 844-852.